Skip to content

Study · Not a test of the peptide alone · 1995

1 result

Dexamethasone enhances insulin-like growth factor-I effects on skeletal muscle cell proliferation. Role of specific intracellular signaling pathways.

Giorgino F, Smith RJ

The Journal of clinical investigation1 Sept 1995Cited by 41 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

  1. 01LabNot a test of IGF-1 LR3 aloneIn vitro (cells)Mechanism

    In skeletal muscle cells, dexamethasone enhanced the actions of the IGF-I analogue long R3IGF-I, similar to its effects on insulin and PDGF-BB, so IGF-binding proteins did not explain it.

    In plain wordsIn muscle cells in the lab, dexamethasone boosted the action of long R3IGF-I, just as it did for insulin and PDGF-BB.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseDexamethasone effect on the action of long R3IGF-I
    Study

    n: not reported in source

    Skeletal muscle cells
    Outcome group
    Muscle injury and repair · Musculoskeletal

    Source sentences

    Summary
    The effect of dexamethasone is not mediated by changes in IGF-binding proteins, as evidenced by similar effects of dexamethasone on the actions of insulin, PDGF-BB, and the IGF-I analogue long R3IGF-I.
    2 context sentences
    Summary · context
    IGF-I stimulation of cell proliferation and c-Fos expression in skeletal muscle cells is markedly enhanced by dexamethasone.
    Title · context
    Dexamethasone enhances insulin-like growth factor-I effects on skeletal muscle cell proliferation. Role of specific intracellular signaling pathways.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.